Novo Nordisk's (NOVOB.DK) shares dip about 16% due to the company lowering its full-year 2025 sales and operating profit outlook. Previously, investors had higher expectations for Novo Nordisk’s growth rates, but the updated guidance now forecasts sales growth in the 8–14% range for the year, which is below earlier projections (13-21%).
Today’s moves are largely due to weaker-than-expected Wegovy sales in the U.S. obesity market. The updated sales outlook specifically cites reduced growth expectations for Wegovy in the U.S., as well as slower-than-expected market expansion and stronger competition, particularly from Eli Lilly's rival drug Zepbound.
NOVOB shares are back at multi-year lows after cutting forecast. Source: xStation
Oracle is laying off thousands of employees — AI is replacing jobs🤖
BREAKING: IRGC threatens to attack Microsoft, Apple, and Alphabet ⚔️
BREAKING: US Labor Market Cools While Consumer Confidence Beats
Marvell Gains as NVIDIA Injects $2 Billion